Diagnostic performance of a streamlined 18 F-choline PET-CT protocol for the detection of prostate carcinoma recurrence in combination with appropriate-use criteria

Published on Jul 1, 2018in Clinical Radiology2.118
· DOI :10.1016/J.CRAD.2018.03.018
R. Frood6
Estimated H-index: 6
(Leeds Teaching Hospitals NHS Trust),
J. Baren1
Estimated H-index: 1
(Leeds Teaching Hospitals NHS Trust)
+ 3 AuthorsAndrew Scarsbrook29
Estimated H-index: 29
(Leeds Teaching Hospitals NHS Trust)
Aim To evaluate the efficacy of single time-point half-body (skull base to thighs) fluorine-18 choline positron emission tomography-computed tomography (PET-CT) compared to a triple-phase acquisition protocol in the detection of prostate carcinoma recurrence. Materials and methods Consecutive choline PET-CT studies performed at a single tertiary referral centre in patients with biochemical recurrence of prostate carcinoma between September 2012 and March 2017 were reviewed retrospectively. The indication for the study, imaging protocol used, imaging findings, whether management was influenced by the PET-CT, and subsequent patient outcome were recorded. Results Ninety-one examinations were performed during the study period; 42 were carried out using a triple-phase protocol (dynamic pelvic imaging for 20 minutes after tracer injection, half-body acquisition at 60 minutes and delayed pelvic scan at 90 minutes) between 2012 and August 2015. Subsequently following interim review of diagnostic performance, a streamlined protocol and appropriate-use criteria were introduced. Forty-nine examinations were carried out using the single-phase protocol between 2015 and 2017. Twenty-nine (69%) of the triple-phase studies were positive for recurrence compared to 38 (78%) of the single-phase studies. Only one patient who had a single-phase study would have benefited from a dynamic acquisition, they have required no further treatment or imaging and are currently under prostate-specific antigen (PSA) surveillance. Conclusion Choline PET-CT remains a useful tool for the detection of prostate recurrence when used in combination with appropriate-use criteria. Removal of dynamic and delayed acquisition phases reduces study time without adversely affecting accuracy. Benefits include shorter imaging time which improves patient comfort, reduced cost, and improved scanner efficiency.
📖 Papers frequently viewed together
#1Michael S. HofmanH-Index: 44
#2Rodney J. HicksH-Index: 90
Last. Matthias EiberH-Index: 55
view all 4 authors...
Prostate-specific membrane antigen PET is rapidly emerging as the new imaging modality standard of reference for prostate cancer, with superior sensitivity and specificity compared to those of conventional imaging modalities.
109 CitationsSource
#1David A. Woodrum (Mayo Clinic)H-Index: 31
#2Akira Kawashima (Mayo Clinic)H-Index: 50
Last. Lance A. Mynderse (Mayo Clinic)H-Index: 29
view all 4 authors...
In 2016, it is estimated 180,890 men are newly diagnosed with prostate cancer and 3,306,760 men live with prostate cancer in the United States. The introduction of multiparametric (mp) magnetic resonance imaging (MRI) of the prostate, standardised interpretation guidelines such as Prostate Imaging Reporting and Data System (PI-RADS version 2), and MRI-based targeted biopsy has improved detection of clinically significant prostate cancer. Accurate risk stratification (Gleason grade/score and tumo...
28 CitationsSource
#1Johannes SchwenckH-Index: 10
#2Hansjoerg Rempp (University of Tübingen)H-Index: 6
Last. Christian la Fougère (DKFZ: German Cancer Research Center)H-Index: 41
view all 8 authors...
Purpose Prostate-specific membrane antigen (PSMA) is expressed ubiquitously on the membrane of most prostate tumors and its metastasis. While PET/CT using 11C-choline was considered as the gold standard in the staging of prostate cancer, PET with radiolabelled PSMA ligands was introduced into the clinic in recent years. Our aim was to compare the PSMA ligand 68Ga-PSMA-11 with 11C-choline in patients with primary and recurrent prostate cancer.
179 CitationsSource
#2Maria PicchioH-Index: 59
Last. Glenn Bauman (UWO: University of Western Ontario)H-Index: 53
view all 5 authors...
Abstract Context 68 Gallium prostate-specific membrane antigen (PSMA) ligand 68 Ga-HBED-CC-PSMA ( 68 Ga-PSMA) is a promising radiotracer for positron emission tomography (PET)/computed tomography (CT) of prostate cancer. Objective To conduct a meta-analysis to evaluate detection rate, diagnostic test accuracy, and adverse effects of 68 Ga-PSMA PET/CT or PET/magnetic resonance imaging (MRI) for staging of prostate cancer and for restaging of rising prostate-specific antigen (PSA) after initial tr...
128 CitationsSource
#1Christina Bluemel (UCLA: University of California, Los Angeles)H-Index: 21
#2Markus Krebs (Ansbach)H-Index: 10
Last. Ken HerrmannH-Index: 67
view all 16 authors...
Investigating the value of 68Ga-PSMA-PET/CT in biochemically recurring prostate cancer patients with negative 18F-choline-PET/CT. One hundred thirty-nine consecutive patients with biochemical recurrence after curative (surgery and/or radiotherapy) therapy were offered participation in this sequential clinical imaging approach. Patients first underwent an 18F-choline-PET/CT. If negative, an additional 68Ga-PSMA-PET/CT was offered. One hundred twenty-five of 139 eligible patients were included in ...
139 CitationsSource
#2Daniele Di BiagioH-Index: 5
Last. Ferdinando Calabria (National Research Council)H-Index: 17
view all 5 authors...
Purpose To investigate the performance of 18F-fluorocholine (18F-FCH) PET/CT in relation to the prostate-specific antigen (PSA) kinetic indexes, PSA doubling time (PSAdt) and PSA velocity (PSAve), in detecting recurrent prostate cancer (PC) in a selected population of patients treated with radical prostatectomy and with PSA ≤2 ng/ml.
23 CitationsSource
#1Stefano FantiH-Index: 83
#2Silvia MinozziH-Index: 51
Last. Arturo Chiti (Humanitas University)H-Index: 54
view all 8 authors...
Purpose For the last decade PET and PET/CT with 11C-choline have been proposed for the evaluation of prostate cancer (PC), but the diagnostic performance of 11C-choline PET/CT is still a matter of debate. We performed a comprehensive review of the most important clinical application of 11C-choline PET, restaging of patients with biochemical relapse, following a rigorous methodological approach and including assessment of the risk of bias. We conducted a systematic review and meta-analysis of the...
146 CitationsSource
#1Marino CimitanH-Index: 10
#2Laura EvangelistaH-Index: 22
Last. Eugenio BorsattiH-Index: 12
view all 14 authors...
The objective of this study was to explore the ability of the initial Gleason score (GS) to predict the rate of detection of recurrent prostate cancer (PCa) with 18 F-choline PET/CT in a large cohort of patients. Methods: Data from 1,000 patients who had undergone 18 F-choline PET/CT because of biochemical evidence of relapse of PCa between 2004 and 2013 were retrieved from databases at 4 centers. Continuous data were compared by the Student t test or ANOVA, and categoric variables were compared...
60 CitationsSource
#1Giuseppe SimoneH-Index: 27
#2Giovanni Battista Di Pierro (Sapienza University of Rome)H-Index: 13
Last. Michele GallucciH-Index: 44
view all 9 authors...
Purpose To highlight a new imaging acquisition protocol during 18F-fluorocholine PET/CT in patients with biochemical recurrence after RP.
14 CitationsSource
#1David M. Schuster (Emory University)H-Index: 33
#2Cristina Nanni (UNIBO: University of Bologna)H-Index: 54
Last. Mark M. Goodman (Emory University)H-Index: 50
view all 17 authors...
Anti-1-amino-3-F-18-fluorocyclobutane-1-carboxylic acid (F-18-FACBC) is a synthetic amino acid analog PET radiotracer undergoing clinical trials for the evaluation of prostate and other cancers. We aimed to describe common physiologic uptake patterns, incidental findings, and variants in patients who had undergone F-18-FACBC PET. Methods: Sixteen clinical trials involving 611 F-18-FACBC studies from 6 centers, which included dosimetry studies on 12 healthy volunteers, were reviewed. Qualitative ...
100 CitationsSource
Cited By2
#2C. HeimburgerH-Index: 6
Last. Alessio Imperiale (UDS: University of Strasbourg)H-Index: 22
view all 6 authors...
INTRODUCTION Despite the increasing use of 18 F-fluorocholine (18 F-FCH) positron emission tomography (PET) in patients with prostate cancer, the acquisition protocol remains debated. We have evaluated the influence of the pelvic dynamic phase on the final reading of whole-body 18 F-FCH PET, to assess the need for a two-stage protocol. Reading the physician's experience and patient's previous treatment profile was also considered as potential influencing factors on final PET interpretation. METH...
#1Manil Subesinghe ('KCL': King's College London)H-Index: 12
#2Meghana Kulkarni ('KCL': King's College London)H-Index: 2
Last. Gary Cook ('KCL': King's College London)H-Index: 62
view all 3 authors...
Prostate cancer is the commonest malignancy to affect men in the United Kingdom. Extraprostatic disease detection at staging and in the setting of biochemical recurrence is essential in determining treatment strategy. Conventional imaging including computed tomography and bone scintigraphy are limited in their ability to detect sites of loco-regional nodal and metastatic bone disease, particularly at clinically relevant low prostate-specific antigen levels. The use of positron emission tomograph...